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Abstract:  
Background: The schizophrenia-associated BRD1 gene encodes a transcriptional regulator whose 
comprehensive chromatin interactome is enriched with schizophrenia risk genes. However, the 
biology underlying the disease association of BRD1 remains speculative.  
Methods: This study assessed the transcriptional drive of a schizophrenia-associated BRD1 risk 
variant in vitro. Accordingly, to examine the effects of reduced Brd1 expression, we generated a 
genetically modified Brd1
+/-
 mouse and subjected it to behavioral, electrophysiological, molecular, 
and integrative genomic analyses with focus on schizophrenia-relevant parameters.  
Results: Brd1
+/-
 mice displayed cerebral histone H3K14 hypo-acetylation and a broad range of 
behavioral changes with translational relevance to schizophrenia. These behaviors were 
accompanied by striatal dopamine/serotonin abnormalities and cortical excitation-inhibition 
imbalances involving loss of parvalbumin immunoreactive interneurons. RNAseq analyses of 
cortical and striatal micropunches from Brd1
+/-
 and wild-type mice revealed differential expression 
of genes enriched for schizophrenia risk including several schizophrenia GWAS risk genes (e.g. 
calcium channel subunits (Cacna1c and Cacnb2), cholinergic muscarinic receptor 4 (Chrm4), 
dopamine receptor D2 (Drd2), and transcription factor 4 (Tcf4)). Integrative analyses further found 
differentially expressed genes to cluster in functional networks and canonical pathways associated 
with mental illness and molecular signaling processes (e.g. glutamatergic, monaminergic, calcium, 
cAMP, DARPP-32, and CREB signaling).  
Conclusions: Our study bridges the gap between genetic association and pathogenic effects and 
yields novel insights into the unfolding molecular changes in the brain of a new schizophrenia 
model that incorporates genetic risk at three levels: allelic, chromatin interactomic, and brain 
transcriptomic.  
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Introduction 
Schizophrenia is a common and severe mental disorder. It is highly heritable with a notably 
polygenic genetic architecture comprising thousands of risk variants (1; 2). The distal part of 
chromosome 22q has long been implicated with schizophrenia (3; 4) and a susceptibility locus at 
22q13.3 has been identified in the isolated population of the Faroe Islands (5). The BRD1 gene, 
which is located within this locus, has repeatedly been associated with schizophrenia in large 
Caucasian case-control samples (6; 7) and the BRD1 promoter SNP rs138880 was recently 
identified as the most significantly associated variant in a large schizophrenia GWAS meta-analysis 
(11,185 cases and 10,768 controls) and family-based replication study (6,298 individuals including 
3,286 cases) (8). Although the BRD1 locus falls short of genome-wide significance in the 
Psychiatric Genomics Consortium (PGC) schizophrenia mega-GWASs using traditional statistical 
methods (p=4.38E-05 in PGC1 (1) and p=3.31E-07 in PGC2 (2)), the locus is found genome-wide 
significant and predicted to be highly replicable when applying an Empirical Bayes statistical 
approach already in the PGC1 dataset (9).  
BRD1 encodes the bromodomain-containing protein 1 (BRD1) which has been identified in 
complexes possessing acetyltransferase activity towards histone H3 (10) – in particular H3K14 
(11). In cell lines, BRD1 is found attached to genomic regions, primarily close to transcription start 
sites, and it has been demonstrated to influence the expression of large gene sets (11; 12). Pointing 
to an involvement of BRD1 as a regulatory hub gene in brain development and susceptibility to 
mental illness, the BRD1 chromatin interactome is significantly enriched for schizophrenia risk  – 
and in particular with genes acting in signaling pathways important during neurodevelopment (12). 
In line with this, BRD1 is essential during embryogenesis as inactivation of both alleles of Brd1 in 
mice leads to compromised eye development, neural tube closure, and a lethal maturation defect in 
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embryonic hematopoiesis (11). Although its cortical expression level peaks during intrauterine 
development (13), BRD1 remains widely and abundantly expressed in the adult mammalian central 
nervous system (6; 14) and a role in the postnatal brain has been indicated by its differential 
regulation in various brain regions in rats upon both electroconvulsive seizures (15) and chronic 
restraint stress (16). Combined, current data suggest that BRD1 is important for both pre- and 
postnatal transcriptional regulation in the brain and could contribute to schizophrenia etiopathology 
by influencing histone modification and thereby the chromatin state around multiple schizophrenia 
risk genes.  
In the present study, we show that human BRD1 promoter risk alleles correlate with reduced BRD1 
mRNA and reduced transcriptional drive. We demonstrate that genetically engineered mice (Brd1
+/-
 
mice) with reduced Brd1 expression and cerebral H3K14 hypoacetylation recapitulate key features 
of schizophrenia symptomatology and neurochemistry. Through a range of molecular, cellular, and 
bioinformatic investigations, including transcriptome profiling of selected brain regions, we provide 
novel insight into the biological changes that underlie the phenotypes and suggest links relevant to 
schizophrenia etiopathology. 
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Methods and Materials 
 
eQTL analysis 
cis-eQTL analysis was performed on the HapMap phase III dataset for CEU (n=55) individuals 
including SNPs located within 35 kb upstream and 10 kb downstream from the transcriptional start 
site of BRD1. Cis-eQTL effects of SNPs in LD with risk alleles were similarly assessed in the 
Blood eQTL browser (http://genenetwork.nl/bloodeqtlbrowser/) (17), BrainCloud Web site (http:// 
braincloud.jhmi.edu/downloads.htm) and GTEx V6 (http://www.gtexportal.org/home/). For further 
details, see Supplemental Methods and Materials. 
Dual luciferase assay of BRD1 promoter fragments  
Genomic DNA from two in-house control subjects homozygous for the A or C allele of the 
rs138880 SNP was used as templates to PCR amplify a 1031 bp region of the promoter potentially 
driving the transcription of the short exon 7 variant of BRD1. Both subjects provided written, 
informed consent for participation, and approval was obtained from local ethics committees. See 
Supplemental Methods and Materials for details. 
Animals 
A mouse line heterozygous for a targeted deletion within the Brd1 gene, Brd1
tm1569.2Arte
 (Brd1
+/−
) 
was generated by TaconicArtemis GmbH (Cologne, Germany) using a targeting vector (pBrd1 
Final cl 1 (UP0257)) with loxP sites flanking exon 3-5 of the Brd1 gene. For further details, see 
Supplemental Methods and Materials. Animal experiments were performed according to 
institutional and national regulations. 
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Quantitative reverse transcription-PCR and Western blotting 
Detailed information on quantitative reverse transcription-PCR and Western blotting procedures can 
be found in Supplemental Methods and Materials.  
Morphological analysis of embryos and general assessment of health, physiology, neurology, and 
motor coordination  
Details on morphological analysis of embryos as well as growth curves, organ and bone measures, 
hematology, functional observation battery, acute pain response, hidden food retrieval test for 
olfaction, rotarod, balance beam walking, and footprinting on adolescent mice can all be viewed in 
Supplemental Methods and Materials. 
Behavioral phenotyping 
Detailed description of social interaction, three-chamber sociability and preference for novelty test, 
spontaneous alternation, continuous alternation, and contextual fear conditioning, associative 
memory retrieval, prepulse inhibition (PPI), spontaneous- and drug-induced hyperactivity, PTZ-
induced seizures and drugs used in testing can all be found in Supplemental Methods and 
Materials. 
Quantification of neurotransmitters 
Mice were sacrificed by cervical dislocation and striatal tissue was collected by free-hand dissection 
and processed for HPLC analyses. For details on HPLC protocols, see Supplemental Methods and 
Materials. 
Brain slice electrophysiology 
Whole-cell patch-clamp recordings of GABAA-receptor-mediated currents were performed in acute 
coronal brain slices of 7-8 weeks old male mice (number of mice (n) in Tables S5). For details see 
Supplemental Methods and Materials.   
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RNAseq analysis on tissue micropunches 
Briefly, brains from adolescent mice were snap frozen in 2-methylbutane and sectioned (1 mm) 
coronally at -20°C. aCC and striatum (caudate nucleus) were identified (18) and punched by a 
needle (1 mm diameter). RNAseq experiments and analyses were performed as previously 
described (19). For details and validation of DEGs, see Supplemental Methods and Materials. 
Immunohistochemistry and stereology  
Brains from 8 weeks old formaldehyde perfused mice were moulded in Tissue-Tek
®
 (Sakura, 
Tokyo, Japan). 40 μm coronal sections containing aCC (Bregma 1.5 mm. to 0.5 mm.) were cut at -
20°C using a MICROM HM355 cryostat and immunohistochemically stained with an antibody 
directed against Parvalbumin (Pvalb). For more details and description of stereological measures 
see Supplemental Methods and Materials.  
Enrichment analysis of DEGs 
Gene set analysis was performed with MAGMA (20) using default settings, based on summary 
statistics from the PGC2 schizophrenia GWAS (2) and other publicly available GWASs  while 
excluding the MHC region and imputed SNPs with info score < 0.8. The gene annotation files 
consisted of lists of genes detected in aCC, striatum, and the two regions combined. See 
Supplemental Methods and Materials for details. 
Analysis of overlap between DEGs and genes located in schizophrenia GWAS risk loci 
The significance of overlap between the set of DEGs and genes in schizophrenia GWAS risk loci, 
as defined by others (2), was analyzed using permutation analysis based on the combined transcripts 
detected in striatum and in aCC (n=42,198) for which human homologous genes exist (n=20,958). 
In each permutation a gene set was sampled with the same number of genes as the DEG set, and 
containing genes of similar sizes as the genes in the DEG set. The p value of the significance of the 
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overlap was estimated as the number of permuted gene sets that contained equally many or more 
genes present in schizophrenia GWAS loci as the set of nominally significant DEGs, divided by the 
total number of permutations. 
Statistical analysis 
STATA 12.1 (StataCorp LP, Texas, U.S.) and GraphPad Prism 5.01 software (GraphPad software, 
San Diego, CA, USA) was used for statistical analysis of animal data and OriginPro9 (OriginLab 
Corporation, Northampton, MA, U.S.) for electrophysiological recordings (see respective result 
sections and figure legends for details).  
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Results 
 
Correlation between BRD1 risk alleles and BRD1 expression 
Due to the location of the rs138880 SNP in a putative BRD1 promoter binding site for 
transcriptional repressor HES1 (6), we assessed the association between the SNP and BRD1 
expression in a cis-eQTL analysis using a publically available dataset with expression phenotypes 
of B lymphoblastoid cell lines established from HapMap3 individuals (21). We found that carriers 
of the rs138880 risk allele (C allele) expressed significantly less BRD1 mRNA than non-carriers 
among individuals of European ancestry (Figure 1A, p<0.05 and Table S1). SNPs in high LD with 
rs138880 were likewise correlated with BRD1 mRNA levels, including all reported SNPs in BRD1 
that have shown association with schizophrenia (6–8; 22) (Figure S1 and Table S1). The same 
effect was seen for SNPs in the haploblock in a larger blood eQTL dataset (5,311 individuals, 
p=9.0E-07, Z-score =-5.2 for the most significant SNP) (17) and similarly in a relatively small brain 
eQTL dataset for a SNP (rs7410537) in strong LD with rs138880 (Figure 1B, 112 individuals, 
p=0.08) (13) whereas no significant BRD1 cis-eQTLs were found in the GTEx database (23). 
To investigate whether particularly the rs138880 alleles have different transcriptional drive, we 
cloned the promoter region harboring either the A or C allele of rs138880 (and otherwise being 
100% identical) into a luciferase reporter vector (Figure 1C). Four independent transfections of 
these vectors into mouse neuroblastoma Neuro2A cells (with co-transfection of a pRL-TK vector 
for normalization) revealed that transcriptional drive was significantly lower for the fragment 
containing the risk C allele (Figure 1C and Figure S2). 
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Generation and basic characterization of heterozygous Brd1
+/−
 mice 
In order to examine the behavioral and underlying neurophysiological and molecular consequences 
of reduced Brd1 expression, we generated a strain of heterozygous Brd1
tm1569.2Arte
 (Brd1
+/−
) mice 
carrying a deletion of exon 3-5 of the Brd1 gene (Figure 1D and Figure S3A). The deletion is 
expected to target all annotated transcript variants of the gene by introducing a premature stop 
codon in exon 6. Brd1 mRNA expression was reduced to approximately 50% in Brd1
+/-
 mice 
compared to wild type (WT) mice in all tissues examined (Figure 1E and Figure S3B-E). This was 
substantiated by Western blotting analysis of whole brain extracts, showing a reduction in 
immunoreactive BRD1 protein ranging between 30-48% (Figure 1F and Figure S3F). Brd1
+/-
 mice 
were healthy and overall physiologically indistinguishable from WT mice (Figure S4 and 
Supplemental results).  
In line with BRD1’s role as a transcriptional regulator in the brain and in accordance with what has 
previously been reported in erythroblasts derived from BRD1 depleted mice (11), we found that 
global cerebral H3K14 acetylation was reduced by ~19% in male Brd1
+/-
 mice (Figure 1G, 
p<0.05).   
Behavioral assessment of heterozygous Brd1
+/−
 mice 
Given the genetic association of BRD1 with schizophrenia and the enrichment of schizophrenia risk 
genes in its chromatin interactome, we assessed the performance of Brd1
+/-
 male mice in a 
comprehensive panel of behavioral tasks (Table 1) designed to evaluate whether reduced Brd1 
expression elicits behavioral changes with translational relevance to schizophrenia symptomatology 
(24–27) - either at baseline or in response to psychotomimetic drugs.  
Social behavior, cognition and information processing 
To investigate behaviors with face validity to negative symptoms in schizophrenia, we observed the 
social behavior of Brd1
+/-
 mice in a test for direct social interaction. Brd1
+/-
 mice did not differ from 
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WT littermates on total time spent investigating an unfamiliar mouse of same genotype (Figure 
2A). However, they spent less time engaged in passive interactions (Figure 2A, p<0.05), 
aggressive behavior was almost exclusively displayed by Brd1
+/-
 mice (Figure 2A, p<0.05), and 
they showed a significant increase in latency to first social interaction (Figure 2B, p<0.01).  
In a test for sociability and preference for social novelty, Brd1
+/-
 mice lacked the preference for 
social stimuli in the form of prioritized exploration of a real mouse over a toy mouse (Figure 2C, 
p<0.001). They, however, acknowledged formerly introduced mice by displaying preferential 
exploration of novel mice over familiar mice to the same degree as did WT mice (Figure 2D). In an 
extension of this test, we exposed target mice to the same “novel” mouse (now familiar) and a new 
novel mouse a week after the first test to assess long-term social recognition memory. In this 
setting, Brd1
+/-
 mice displayed significantly less preference investigating the new novel mice 
compared to WT mice (Figure 2E, p<0.05).  
In the fear conditioning test for associative learning and contextual long term memory, levels of 
pre-training (basal) freezing did not differ between genotypes (Figure 2F). However, Brd1
+/-
 mice 
spent significantly less time freezing compared to WT mice during the acquisition phase (Figure 
2F, genotype effect, F1,20=8.142,  p<0.01) and following post-acquisition recording (Figure 2F, 
p<0.05), whereas motor activity did not differ between the groups (Figure S5J). Supportive of a 
deficit in long term memory, as indicated in the test for social recognition memory, Brd1
+/-
 mice 
displayed less time freezing than WT mice when re-introduced to the context box 3 days after 
acquisition (Figure 2G, p<0.01), more prominently 7 days after acquisition (Figure 2G, p<0.001) 
compared to freezing 1 hour after acquisition, and with a clear decline of freezing behavior in 
Brd1
+/-
 mice over time (Figure 2G, p<0.05). In tests for working memory, Brd1
+/-
 mice performed 
significantly worse than their WT littermates when treated with a low dose of the NMDA receptor 
antagonist, phencyclidine (PCP, 1.3 mg/kg) (Figure S5K-M and Supplemental results). 
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Sensorimotor gating, as measured by prepulse inhibition of the acoustic startle response (PPI), is 
commonly decreased in individuals with schizophrenia indicating an impaired pre-attentive 
information processing (28; 29). This can be readily assessed in rodents (30; 31) with or without the 
administration of psychotomimetics (32).  
Baseline PPI response was similar in Brd1
+/-
 and WT mice (Figure S5N). Pharmacological 
challenge with both amphetamine and PCP resulted in decreased PPI in treated mice compared to 
saline injected mice across all prepulse intensities. However, whereas Brd1
+/-
 and WT mice did not 
differ on PPI upon amphetamine challenge (Figure S5O), a high dose of PCP (5 mg/kg) caused 
significantly decreased PPI in Brd1
+/- 
mice compared to WT mice at 15 db intensity (Figure 2H, 
p<0.05).  See Figure S5P-R and Supplemental Results for data on the acoustic startle responsivity 
(ASR) in Brd1
+/-
 mice. 
Drug responsivity, striatal neurochemistry, and transcriptome profiling 
Novelty- and drug-induced hyperactivity are established rodent models of positive symptomatology 
in schizophrenia enabling detection of underlying neurotransmitter changes (33). Baseline 
locomotor activity appeared similar in Brd1
+/-
 and WT mice with both groups showing gradual 
habituation to the test environment (Figure 3A, C and Figure S6).   
Treatment with PCP, amphetamine, and cocaine all increased the activity of mice (Figure 3A, C 
and Figure S6). While no significant difference in induced activity was found between Brd1
+/-
 and 
WT mice at a lower dose of PCP (2.5 mg/kg), a high dose (5 mg/kg) resulted in significantly 
increased horizontal locomotor activity in Brd1
+/-
 mice (Figure 3A, effect of genotype, F1,22=5.9, 
p<0.05 and Figure 3B, p<0.01) whereas rearing activity remained similar (data not shown). 
Cocaine caused a left-shift in the activity profile at the highest dose (30 mg/kg) with Brd1
+/-
 mice 
reaching peak activity earlier than WT mice (Figure 3C, genotype x time interaction effect, 
F23,506=2.043, p<0.01) but did not result in increased horizontal activity in Brd1
+/-
 mice (Figure 3D). 
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Additionally, Brd1
+/-
 mice responded to even a low dose of cocaine (10 mg/kg) with a significant 
increase in rearing activity compared to WT mice (Figure 3E, p<0.05). Treatment with 
amphetamine did not result in any significant differences in activity between genotypes (Figure 
S6). 
The observed psychotomimetic drug sensitivity in Brd1
+/-
 mice points to changes in several striatal 
neurotransmitter systems - including striatal monoamine neurotransmission, which has traditionally 
been seen as a key pathological process in schizophrenia (34; 35). Accordingly, we measured total 
striatal dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), and 
serotonin (5-HT) levels in tissue extracts and found a significant increase in both DA and 5-HT in 
Brd1
+/-
 mice compared to WT mice (Figure 3F-G, p<0.05), whereas DOPAC and HVA levels 
were similar (Figure 3F). For more data on neurochemistry in Brd1
+/-
 mice see Figure S7 and 
Supplemental Results. 
Due to the putative role of BRD1 as a transcriptional regulator during neurodevelopment and in the 
adult brain, we performed genome-wide transcriptome profiling of tissue micro-punches obtained 
from the dorsal striatum using RNAseq to assess transcriptomic differences between Brd1
+/-
 and 
WT mice. This analysis revealed 1378 nominally significant differentially expressed genes (DEGs; 
397 downregulated and 981 upregulated) of which 269 (37 downregulated and 232 upregulated) 
were significant after Benjamini-Hochberg false discovery rate (FDR) correction at 5% (Table S3). 
Ingenuity Pathway analysis (IPA) of the nominally significant DEGs revealed significant 
enrichment (p<0.05) of pathways including G-protein coupled receptor signaling, cAMP mediated 
signaling, Protein kinase A (PKA) signaling, Dopamine-DARPP-32 feedback in cAMP signaling, 
and CREB (cAMP Responsive Element Binding Protein) signaling as well as DA receptor, 5-HT 
receptor, glutamate receptor, and GABA receptor signaling among others (Table S4). Remarkably, 
the entire annotated network of genes involved with ‘Behavior, Hereditary disorder and 
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Neurological disease’ were represented among the DEGs (p<3E-30), including the typical 
antipsychotic drug target gene and schizophrenia risk gene (2), Drd2, encoding the DA receptor D2 
(Figure S8). Using high throughput qPCR, we validated differential expression of 34 out of 50 
randomly selected FDR significant DEGs in RNA samples extracted from tissue micro-punches 
from independent biological replicates, indicating approximately 70% positive predictive value in 
the performed analysis (Table S3). In support of altered striatal DA transmission, we specifically 
validated both decreased Drd2 mRNA (Table S3) and Drd2 protein levels in Brd1
+/-
 mice (Figure 
3H, p<0.05). 
Neuronal excitability and synaptic inhibition 
As Brd1
+/-
 mice showed increased sensitivity to PCP in tests of cognition and PPI, we speculated 
that imbalanced excitation-inhibition might be a general cerebral feature in Brd1
+/-
 mice. To 
coarsely examine if cortical GABAergic inhibitory tone is affected in Brd1
+/-
 mice, we administered 
mice with various doses of the GABA-A receptor antagonist, PTZ, and observed for seizure 
activity. Brd1
+/-
 mice displayed increased propensity for myoclonic jerks at 70 mg/kg (Figure 4A, 
p<0.05), despite experiencing significantly more recurrent clonic seizures within the session 
(Figure 4B, p<0.05). They further showed decreased latency to clonic seizure onset compared to 
WT mice across all doses (Figure 4C, p<0.05), whereas the fraction that experienced clonic-tonic 
seizures was the same (Figure S9).    
In order to assess inhibition at the synaptic level, we performed whole-cell patch-clamp recordings 
of inhibitory postsynaptic currents from pyramidal neurons in layers 2/3 of the aCC in acute coronal 
brain slices. In the presence of kynurenic acid, an inhibitor of ionotropic glutamate receptors, we 
found a ~40% decrease in the frequency of spontaneous inhibitory postsynaptic currents (sIPSCs) in 
Brd1
+/-
 compared to WT mice (Figure 4D-E and H, Table S5, p<0.05). We repeated the 
experiments in the presence of the Na
+
 channel blocker, tetrodotoxin (TTX), to isolate miniature 
 Qvist et al. 16 
 
IPSCs (mIPSCs) and found a ~38% decrease in their frequency (Figure 4F-G and I; Table S5, 
p<0.01). There was no significant difference in sIPCSs or mIPSCs mean amplitudes (Figure 4J-K; 
Table S5) or time parameters between Brd1
+/-
 and WT mice. Similar findings were made in 
pyramidal neurons of the somatosensory cortex (Table S5), supporting a widespread cerebral 
GABAergic dysfunction in Brd1
+/-
 mice.  
Cortical gene expression profiling and Pvalb immunohistochemistry 
Addressing the molecular mechanisms underlying altered cortical inhibition in Brd1
+/-
 mice, we 
performed transcriptional profiling on RNA extracted from aCC tissue micro-punches by RNAseq. 
The analysis revealed 919 nominally significant DEGs (451 downregulated and 468 upregulated) of 
which 118 (61 down-regulated and 57 up-regulated) were significant after FDR correction at 5% 
(Table S6). Although less convincing than for DEGs detected in striatum, by IPA pathway analyses 
nominally significant DEGs were found to cluster in several canonical pathways (p<0.05)(Table 
S7), including TGF-β signaling, Dopamine-DARPP32 feedback in cAMP signaling, and in 
accordance with the observed increase in PCP sensitivity, Glutamate receptor signaling. In the 
latter, genes encoding ion channels (Grik3, Grik5, Grid2, Grin2b, and Grin2d), G-protein coupled 
receptors (Grm1 and Grm2), post-synaptic density protein (Dlg4), and vesicular glutamate 
transporter (Slc17a7) were upregulated whereas Homer1, encoding a post-synaptic density 
scaffolding protein, was down-regulated in Brd1
+/-
 mice (Figure S10). In relation to altered 
inhibitory signaling in Brd1
+/-
 mice, the marker for fast-spiking interneurons, Pvalb, was 
significantly downregulated by ~25% (Table S6). To assess whether this reduction in Pvalb mRNA 
was associated with a reduction in the number of Pvalb immunoreactive cells, we further estimated 
the number of this sub-class of interneurons in the aCC by immunohistochemistry coupled with 
stereological counting and found an overall ~28% reduction (Figure 4L, p<0.05).  
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Identification of DEG upstream regulators 
Overall, nominally significant DEGs identified in aCC overlapped significantly with those 
identified in striatum (Table S6, Chi
2
, p<0.001).  
Supportive of a common regulatory mechanism underlying the transcriptomic changes seen in 
different brain regions, IPA upstream regulator analyses of the nominally significant DEGs 
identified in striatum and aCC, respectively, both pointed to CREB1, BDNF, and HTT as the most 
likely upstream regulators of the DEGs (Table S8, p<1E-5 for all). Strikingly, this similarity in 
upstream regulators of the DEGs occurred despite a limited overlap in the specific DEGs 
identifying these regulators in the two brain regions investigated (Table S8). Since phosphorylation 
and thus activation of CREB is the downstream effect of GPCR-cAMP-DARPP-32 signaling (36) 
and DEGs from both striatum and aCC cluster in this pathway, we investigated Creb 
phosophorylation  in whole-brain protein extracts. We found that Creb was hyper-phosphorylated in 
Brd1
+/-
 mice compared to WT mice (Figure 5A, p<0.05) and further, that its transcriptional target, 
c-Fos, was significantly more abundant (Figure 5A, p<0.05).  
Schizophrenia risk enrichment in DEG sets 
Using summary statistics from the largest to date schizophrenia GWAS (2), we assessed risk 
enrichment by MAGMA (20) analysis of DEGs from both aCC and striatum - and the two regions 
combined. Interestingly, we found that DEGs from each brain region, separately, was enriched with 
schizophrenia risk (Figure S11, p<0.05) and more significantly when the two regions were assessed 
collectively (Figure S11, p<0.01). In a secondary exploratory analysis, we assessed whether DEGs 
were enriched for common variant risk in other disorders/traits. Besides from DEGs in aCC, which 
showed enrichment for bipolar disorder (Figure S11, p<0.05), no risk enrichment was seen for 
other brain and non-brain disorders/traits (Figure S11). In line with the identified schizophrenia risk 
enrichment, we found that a significant higher proportion of striatum and aCC DEGs localize to 
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genome-wide significant schizophrenia risk loci than expected by chance (Table S9, p<0.01), 
including loci containing e.g. the calcium channel subunits genes, Cacna1c and Cacnb2, the 
cholinergic muscarinic receptor 4 gene, Chrm4, Drd2, and the transcription factor 4 gene, Tcf4. 
Noteworthy in this context, the 3’UTR of BRD1 contains a conserved target site for microRNA-
137, which is also is located in a schizophrenia GWAS locus (37).  
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Discussion 
BRD1 is located in a 150 kb haploblock comprising the four genes ALG12, CRELD2, 
ZBED4, and BRD1. In addition to the genetic associations and the schizophrenia risk enrichment of 
BRD1’s chromatin interactome reported previously (12), the present study provides evidence 
strongly suggesting BRD1 as the causal risk gene within the locus. We show that BRD1 
schizophrenia risk alleles correlate with reduced BRD1 expression and we provide direct in vitro 
evidence that the rs138880 risk allele lowers transcriptional drive. Moreover, we generate mice with 
reduced Brd1 expression and find that they display hypersensitivity to psychostimulants and 
behavioral abnormalities with translational relevance to schizophrenia symptomatology along with 
changes in neuro-chemistry and –transmission reminiscent of findings in schizophrenia. In 
accordance with a central role for BRD1 as a transcriptional regulator in the brain, we establish that 
decreased expression of Brd1 in mice leads to cerebral histone H3K14 hypo-acetylation and 
extensive changes in expression of genes that are enriched for schizophrenia risk and cluster in 
functional networks associated with mental disorders. Finally, it may be noted that neurological 
screenings of knockout mouse models for Creld2 and Zbed4 have not revealed phenotypes with 
translational relevance to schizophrenia symptomatology (38). 
Schizophrenia is a highly polygenic disorder with small effect sizes of the implicated 
common risk variants. The rs138880 BRD1 promoter variant contribute to schizophrenia risk with 
an estimated odds ratio of around 1.1 (8), which is likely reflected in the discrete expression 
phenotypic effect that we observe in risk allele carriers. Hence, the Brd1
+/-
 mouse with a ~50% 
reduction of Brd1 expression does not exactly reflect the effect associated with the risk allele, but 
rather demonstrate the molecular and functional consequences of hampered BRD1 expression. 
However, despite BRD1 being very intolerant to loss of function mutations (39), a schizophrenia 
patient carrying a nonsense mutation in BRD1 disrupting the gene in the first exon has recently been 
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detected in a large schizophrenia exome-sequencing study (40), thus more directly parallelizing the 
Brd1
+/-
 mouse. Furthermore, in terms of global cerebral H3 hypo-acetylation – a trait that has been 
shown in young subjects with schizophrenia and which correlate with expression levels of genes 
implicated with psychiatric disorders (41) - this effect in the mice is within a clinically relevant 
range. Finally, by influencing histone modification and thereby the chromatin state around genes in 
its comprehensive schizophrenia risk enriched chromatin interactome, the presented modulation of 
Brd1 expression may be conceived as a way to model the highly polygenic nature of schizophrenia.  
Social behavior, cognition, PCP sensitivity, and cortical neurotransmission  
Negative symptoms reflect a range of deficits in normal emotional responses in individuals 
with schizophrenia. In mice, assessment of this domain is largely confined to tests for social 
interaction and general sociability. Our findings that Brd1
+/-
 mice showed markedly different social 
interaction profiles and impaired ability to recall social identifiers may collectively have 
translational relevance to the social withdrawal (42) and social recognition deficits (43) observed in 
schizophrenia. 
Also with translational relevance to schizophrenia symptomatology (44; 45), we observed clear 
deficits in associative learning in Brd1
+/-
 mice and an accelerated time-dependent loss of acquired 
contextual memories. Indicative of a reduced capacity in the glutamatergic transmission to support 
pre-attentive processing and cognition, Brd1
+/-
 mice displayed increased sensitivity to the disruptive 
effect of PCP on PPI and working memory performance.  
We speculate that primarily altered neurotransmission may underlie the cognitive deficits and 
increased sensitivity to PCP in Brd1
+/-
 mice. In agreement, Brd1
+/-
 mice displayed elevated seizure 
propensity in response to PTZ, suggestive of increased excitability of critical neurocircuitry. 
Furthermore, evaluation of sIPSCs and mIPSCs by patch-clamp recordings from pyramidal neurons 
demonstrated a clear deficit in inhibitory GABAergic synaptic neurotransmission in the aCC, which 
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co-incited with a significant up-regulation of genes encoding glutamatergic receptors and a specific 
decrease in Pvalb immunoreactive fast-spiking interneurons in this tissue.  
In support of altered cortical excitability (46), transcriptome data revealed differential expression of 
DA receptor D1 (Drd1a) and disturbed DA-DARPP-32 signaling which has been linked to 
cognitive performance (47), sensorimotor gating (36), and general prefrontal dysfunction in 
schizophrenia cases (48). 
Psychotomimetic drug response and striatal neuro-chemistry and -signaling  
Positive symptoms arise from altered striatal dopaminergic transmission (49), and psychotic 
symptoms are inducible even in healthy individuals by administration of drugs that increase striatal 
DA activity. Similarly, sensitivity to psychostimulants is used to mimic psychosis-like behavior in 
mice using locomotor activity as a read-out for increased striatal DA activity.  
Decreased levels of Brd1 sensitize mice to both the effect of PCP and cocaine in a manner 
reminiscent of the enhanced sensitivity that individuals with schizophrenia display to 
psychostimulant drugs (50) - but in contrast to what is observed in patients, this sensitization was 
not evident following amphetamine challenge. The locomotor stimulatory effect of PCP is exerted 
through several mechanisms aside from the direct effect of blocking NMDA receptors, including 
actions at DA- and 5-HT receptors (51; 52),  and it has been shown to rely on DARPP-32 facilitated 
striatonigral signaling (53). Amphetamine and cocaine both inhibit the reuptake of monoamines 
and, similar to what has been observed in individuals with schizophrenia (54), both striatal DA and 
5-HT levels were significantly elevated in Brd1
+/-
 mice. However, whereas cocaine relies on DA 
release to exert its effect (55–57), amphetamine mediates its psychomotor-stimulatory effect in a 
firing independent way (58). Striatal DA release is determined by DA release probability (59; 60) 
which is profoundly controlled by cholinergic interneurons in striatum (61). Noteworthy, we found 
that two of the main cholinergic receptors, Chrna2 and Chrm4, responsible for the dynamic control 
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of DA release probability are differentially regulated in striatal tissue of Brd1
+/-
 mice (61) – thus 
offering a possible explanation for the selective drug sensitivity displayed by Brd1
+/-
 mice.  
In concordance with altered DA and 5-HT transmission, transcriptome profiling of striatal tissue 
revealed reduced expression of both DA receptor D1 (Drd1a), D2 (Drd2) and differential 
expression of several 5-HT receptors. The effect of reduced Brd1 expression on the striatal 
transcriptome is, however, widespread and suggests dysregulation of multiple signaling pathways 
that  ultimately appears to converge in the DARPP-32 signaling pathway of striatal medium spiny 
neurons (MSNs) (Figure 5B and Figure S12). Our finding that Creb was globally hyper-
phosphorylated and that its transcriptional target, c-Fos globally more abundant in the Brd1
+/-
 mice 
strongly supports that DARPP-32 signaling is affected. 
 
Enrichment of schizophrenia risk 
Emphasizing the importance of BRD1 as a cardinal transcriptional regulator, we demonstrate 
widespread expression alterations in the brains of Brd1
+/-
 mice. This includes altered expression of 
transcriptional regulators and immediate early genes (IEGs) like Homer, Bdnf, c-fos, c-jun, and 
Shank  which have previously been linked to the etiopathology of mental disorders (62–64). We 
further find that the identified DEGs are enriched for schizophrenia risk and that they cluster within 
known GWAS schizophrenia risk loci. In accordance with this, DEGs group in pathways that 
largely overlap with the recently published pathway analysis of GWAS data (65). Thus, the 
identified pathways are not only centered on calcium signaling and synaptic and postsynapse-
related processes but also comprise diverse immune, hormonal, and signal transduction pathways – 
including CREB (65).  
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 During recent years, the hunt for schizophrenia susceptibility genes through large scale 
GWASs has revealed SNPs statistically associated with the disorder but yet provided little 
information on their functional contribution to the pathogenesis. In general, GWAS-identified 
markers seem to play a major role in the regulation of gene expression rather than the alteration of 
protein sequence (66; 67). We demonstrate that a risk allele in the BRD1 promoter is associated 
with reduced BRD1 expression, which in mice result in widespread transcriptomic changes that to a 
high extent affect schizophrenia risk loci and cluster in networks and pathways associated with 
mental disorders. Reduced Brd1 expression causes epigenetic alterations involving cerebral histone 
H3 hypoacetylation which, in line with the dominating hypotheses of schizophrenia, ultimately 
results in developmental loss of Pvalb immunoreactive interneurons, imbalanced 
excitatory/inhibitory neurotransmission, region-specific changes in monoamine neurochemistry and 
behavioral abnormalities translating to major categories of schizophrenia symptomatology (Table 
1). Underlining the pharmaceutical relevance of the presented neuro-molecular and -chemical 
consequences of Brd1 deficiency, epigenetic therapy has been shown to be effective in treating 
aspects of mental illness (68; 69) and histone deacetylase inhibitor drugs are currently undergoing 
clinical trials for the treatment of cognitive deficits in schizophrenia (70).  
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LEGENDS 
 
Figure 1 
BRD1 schizophrenia risk variants associate with reduced BRD1 expression. (A) Plotted is the 
normalized expression in blood of the ILMN_1730019 probe, which is located in the 3’UTR of the 
BRD1 gene, for rs138880 non-risk (AA) and risk (AC, no homozygous carriers among genotyped 
subjects) allele carriers. (B) Similarly, in cortical tissue the normalized expression of the BRD1 
probe, hHC012627, was plotted for non-risk (GG) and risk (GA/AA) allele carriers of rs7410537 
which is in strong LD with rs138880. (See Figure S1). t test was applied to compare BRD1 
expression between groups. (C) Dual luciferase reporter assay of BRD1 promoter fragments 
containing rs138880 SNP variants (A or C allele) with schematic representation of the genomic 
localization (chr22:50,217,500-50,219,500; GRCh37/hg19) of BRD1 illustrating the 5’UTR 
(narrow line) and the 5’ part of exon 1 (broad line). Random effects meta-analysis of four 
independent luciferase assays (Experiment 1-4, presented in Figure S2B) is presented. For 
experiment 1, the number of replicate transfections are n=6 and for experiments 2-4 the number are 
n=15-16 for the A and C allele. The standardized mean difference (SMD) and 95% CI of 
experiment 1-4 and the total random effects are plotted. SMD=2.82, [95% CI, 1.42 to 4.21]. (D) 
Schematic representation of the WT allele of the mouse Brd1 locus, the targeting construct used for 
homologous recombination in C57BL/6NTac embryonic stem cells (vector backbone omitted for 
clarity), the resulting targeted allele and the mutant allele derived by in vivo CRE-mediated deletion 
of exon 3-5 using a ubiquitously active general CRE deleter. (E) Quantitative RT-PCR analysis of 
Brd1 transcripts derived from whole brain tissue from WT and Brd1
+/-
 mice (n=6 for each 
genotype). Measurements of two different exon border spanning amplicons are shown (exon 3-4 is 
contained within the deleted region, whereas the amplicon spanning exon 11-12 is located outside 
this region in the 3’ end of the Brd1 transcript). Brd1 expression in Brd1
+/-
 mice was 34% (t test, 
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p<0.001) and 58% (t test, p<0.001) lower than in WT mice for respectively, the exon 3-4 and exon 
11-12 amplicons. (F) Western blotting analysis of protein extracts derived from whole brain tissue 
from WT and Brd1
+/-
 mice. Top membrane was incubated with the anti-BRD1-L (AB67) antibody 
(detecting a band of an apparent molecular weight of 150 kDa; predicted molecular weight of 
BRD1-L is 133 kDa), lower membrane half was incubated with an anti-Beta actin antibody 
(detecting a band of an apparent molecular weight of 42 kDa, comparable to the predicted 
molecular weight). Two positive control samples, derived from HEK cell lines stably expressing the 
V5-tagged human BRD1-L or BRD1-S isoforms, respectively, as well as a negative control, were 
analyzed simultaneously and incubated with an anti-V5 antibody. A band migrating similarly to the 
human BRD1-L control was detected in all samples and annotated as the mouse BRD1-L. 
Densitometric analysis of protein amounts is presented. Samples were derived from WT (n=10) and 
Brd1
+/-
 (n=10) mice (1:1 male to female ratio in both groups). Protein amounts in individual 
samples were normalized to the amounts of Beta-actin and plotted as relative means (+ SEM) to the 
average protein amount of the WT group. The average BRD-L protein amount was decreased by 
48% in Brd1
+/−
 mice compared to their WT littermates (t test, p=0.079). A similar result was 
obtained in an independent Western blotting analysis using the same antibody but including 
densitometric analysis of bands derived from samples of pooled whole brain extracts (Figure S3F) 
(G) Level of acetylation at H3K14 relative to the amount of H4 in histone extractions from whole 
brain (WT and Brd1
+/-
 male mice; n=3 for each genotype). Analysis was made by Western blotting 
using the indicated antibodies. Densitometric analysis of relative acetylated H3K14 protein 
amounts, normalized to the amounts of H4, revealed a reduction by ~19% in brains from Brd1
+/-
 
mice compared to WT mice. Comparisons between groups were performed using two-sample 
Student t tests. *p<0.05, **p<0.01. Data shown are mean and SEM for each group unless 
specifically stated otherwise. 
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Figure 2 
Brd1
+/-
 mice display selective deficits in social behavior, impaired performance in tests 
addressing social cognition, learning and memory, and affected pre-attentive processing. (A) 
Social interaction between same genotype mice (Brd1
+/-
 n=10, WT n=10). Brd1
+/-
 mice spend less 
time engaged in social support than WT mice (t test, p<0.05) and display more aggressive 
incidences (zero-inflated poisson regression, IRR=12.67, p<0.05). (B) Brd1
+/-
 mice hesitated for 
longer before engaging in social interaction with partner mice (t test, p<0.01). Bars represent 
latency to first contact between mice. (C) Three chamber test for sociability (Brd1
+/-
 n=12, WT 
n=11). Preference score for time spend investigating a non-social (toy mouse) versus a social 
stimulus (stranger 1) in a 10 min. session. Brd1
+/-
 mice investigated toy mouse (non-social stimulus) 
and a weight-matched unfamiliar mouse (social stimulus) without preference. This is in contrast to 
WT mice, which displayed a clear preference for the social stimulus (t test, p<0.001). (D) Three 
chamber test for social novelty (Brd1
+/-
 n=12, WT n=11). Preference score for time spend 
investigating a familiar mouse (stranger 1) versus an unfamiliar mouse (stranger 2). Brd1
+/-
 and WT 
mice both preferred to investigate a novel social stimulus rather than the previously encountered 
social stimulus (t test, p>0.05). (E) Three chamber test for remote social memory carried out one 
week after former two tests (Brd1
+/-
 n=10, WT n=10). Preference score for time spend with a 
familiar mouse (stranger 2) encountered in the 10 min. session the previous week versus a 
completely new mouse (stranger 3). Brd1
+/-
 mice lacked the preference for novelty displayed be WT 
mice, indicating that the memory of stranger 2 consolidated the previous week was impaired (t test, 
p<0.05). (F) Acquisition of conditioned learning in Brd1
+/-
 mice and WT mice (Brd1
+/-
 n=12, WT 
n=12). Freezing behavior was monitored during a 240 sec. training session that included 4 
exposures to foot shock. Brd1
+/-
 mice spend less time freezing than WT mice, thus demonstrating 
compromised contextual learning (Two-way RMANOVA, effect of genotype, F1,20=8142, p<0.01) 
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with post hoc comparisons showing significantly decreased freezing behavior at exposure 2 
(p<0.05), 3 (p<0.01) and 4 (p<0.05) and post-acquisition (p<0.05). (G) Context dependent memory 
retrieval was measured as freezing behavior in the test box an hour after acquisition and again 3 and 
7 days after acquisition (Brd1
+/-
 n=12, WT n=12). Brd1
+/-
 mice displayed similar freezing behavior 
as WT mice an hour after acquisition, demonstrating that they had learned the relation between 
context and foot shock (t test, p<0.05). When placed in the same context 3 days later, Brd1
+/-
 mice 
showed less freezing behavior than WT mice, indicating that they were less capable of recalling the 
conditioned contextual memory (t test, p<0.01). This was even more prominent when measured 7 
days after acquisition (t test, p<0.001). (H) Mice were tested for PPI in 3 sessions spanning 4 days 
and including habituation to the test paradigm on day 1 (not shown), baseline testing on day 3 (not 
shown), and psychotropic challenge on day 4. Mice were administered a single dose of PCP (5 
mg/kg shown) and tested across 3 intensities (5, 10, and 15db above background level). Brd1
+/-
 
mice were significantly more sensitive to the PPI disruptive effect of 5 mg/kg PCP at 15db above 
background compared to WT mice (Brd1
+/-
 n=13, WT n=11) (t test, p<0.01). Data shown are mean 
and SEM for each group. *p<0.05 **p<0.01 ***p<0.001. 
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Figure 3 
Brd1
+/-
 mice are sensitive to the behavioral effects of psychotomimetics, show region-specific 
changes in tissue neurotransmitter levels, and altered striatal transcriptomic profile. (A) PCP-
induced hyperlocomotion is increased in Brd1
+/-
 mice. Mice were placed in an observation box and 
allowed to acclimate, then injected with PCP and scored for activity as measured by number of 
infra-red beams crossed. Brd1
+/-
 mice exhibited greater sensitivity to 5 mg/kg of PCP than WT mice 
(Brd1
+/-
 n=12, WT n=12) (Two-way RMANOVA, effect of genotype, F1,22=5.9, p<0.01). (B) Bar 
graphs show total accumulative activity during two hours of recording after PCP/vehicle injection. 
Brd1
+/-
 mice exhibited greater sensitivity to 5 mg/kg of PCP than WT mice (Brd1
+/-
 n=12, WT 
n=12) (t test, p<0.01). (C) Brd1
+/-
 show altered hyperactivity response upon challenge with cocaine. 
Setup as described above for PCP (Brd1
+/-
 n=12, WT n=12). Rather than responding with an 
increase in activity, Brd1
+/-
 mice reach peak activity earlier than WT mice when administered 30 
mg/kg of cocaine (Two-way RMANOVA, genotype x time interaction effect, F23,506=2.043, 
p<0.01). (D) but shows no overall increased activity response to any dose of cocaine. (E) Brd1
+/-
 
mice respond with increased rearing activity compared to WT mice at a lowdose of cocaine (10 
mg/kg) (t test, p<0.05). (F) Striatal DA level is elevated in Brd1
+/-
 mice (n=11) compared to WT 
mice (n=10) (t test, p<0.05) whereas DOPAC and HVA levels are similar. (G) 5-HT tissue levels 
were significantly elevated in striatal tissue in Brd1
+/-
 mice (n=14) compared to WT mice (n=16)(t 
test, p<0.05) (H) Western blotting analysis of protein extracts derived from tissue micro-punches 
from right striatum from WT and Brd1
+/-
 mice (n=10 for each genotype). Top membrane was 
incubated with anti-Drd2 antibody and lower part of the membrane with anti-Hprt antibody. 
Densitometric analysis of relative protein amounts, normalized to the amounts of Hprt, showed an 
approximate 50% reduction in Drd2 protein in Brd1
+/-
 mice compared to WT mice. Data shown are 
mean + SEM for each group. *p<0.05. 
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Figure 4 
Brd1
+/-
 mice show deficient GABAergic synaptic neurotransmission, transcriptomic changes, 
and reduced number of parvalbumin immunoreactive neurons in aCC. (A) Mice were 
administered doses of 40, 55, or 70 mg/kg PTZ and observed for seizure activity for 30 min. and for 
tonic seizures for an additional 30 min. Brd1
+/-
 mice (n=12) displayed significantly more jerks at 70 
mg/kg PTZ than WT mice (n=12; t test with Welch’s correction, p<0.05), whereas no difference 
was observed at low and intermediate doses. (B) Several mice went into seizures more than once 
when tested with 70 mg/kg. Brd1
+/-
 mice (n=12) showed significantly more incidences than WT 
mice (n=12; Kruskal-Wallis test, p<0.05) 1
st
, 2
nd
, and 3
rd
 refers to the order of seizure occurrence. 
(C) A tendency was noted with Brd1
+/-
 mice going into clonic seizures earlier than WT mice 
regardless of dose. However, the difference was only significant for the lower dose (Peto-Peto-
Prentice, p<0.05). When adjusting for dose effect, the overall significance level was also significant 
(Peto-Peto-Prentice, combined; p<0.05). (D, E) Whole-cell recordings of spontaneous inhibitory 
postsynaptic currents (sIPSCs) from exemplar aCC pyramidal neurons layer 2/3 in Brd1
+/-
 and WT 
mice. (F, G) Whole-cell recordings of miniature inhibitory postsynaptic currents (mIPSCs) from 
exemplar aCC pyramidal neurons layer 2/3 in Brd1
+/-
 and WT mice. In order to isolate mIPSCs, 
recordings were done in the presence of the Na
+
 channel blocker tetrodotoxin (1 μM). (H) Averaged 
cumulative probability plot showing altered distribution of sIPSC inter-event intervals in aCC layer 
2/3 pyramidal neurons of Brd1
+/-
 mice (WT, black; Brd1
+/-
, red) (Two-sample Kolmogorov-
Smirnov test, p<0.05). Inset: Brd1
+/- 
mice show lower mean frequency of sIPSCs in aCC pyramidal 
neurons layer 2/3 of Brd1
+/- 
mice in comparison to WT mice (Brd1
+/-
: 9.6 ± 1.6 Hz; ncells=13; WT: 
16.8 ± 2.1 Hz, ncells=13) (t test, p<0.05). (I) Averaged cumulative probability plots showing altered 
distribution of mIPSC inter-event intervals in aCC layer 2/3 pyramidal neurons of Brd1
+/-
 mice 
(WT, black; Brd1
+/-
, red) (Two-sample Kolmogorov-Smirnov test, p<0.05). Inset: Brd1
+/- 
mice 
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show lower mean frequency of mIPSCs in aCC pyramidal neurons layer 2/3 in comparison to WT 
mice (Brd1
+/-
: 5.1 ± 0.6 Hz; ncells=16; WT: 8.3 ± 0.7 Hz, ncells=16) (t test, p<0.01). (J) Averaged 
cumulative probability plot showing distribution of sIPSC amplitudes in aCC layer 2/3 pyramidal 
neurons of Brd1
+/-
 mice (WT, black; Brd1
+/-
, red) (Kolmogorov-Smirnov test, p<0.05). Inset: mean 
sIPSCs amplitudes in aCC pyramidal neurons layer 2/3 were similar between Brd1
+/-
 and WT mice 
(Brd1
+/-
: 38.4 ± 2.2 pA, ncells=13; WT: 43.6 ± 2.0 pA, ncells=13). (K) Averaged cumulative 
probability plot showing similar distribution of mIPSC amplitudes in aCC layer 2/3 pyramidal 
neurons of Brd1
+/-
 and WT mice (WT, black; Brd1
+/-
, red). Inset: mean mIPSCs amplitudes in aCC 
pyramidal neurons layer 2/3 were similar between Brd1
+/- 
and WT mice (Brd1
+/-
: 34.5 ± 2.1 pA, 
ncells=16; WT: 35.7 ± 1.7 pA, ncells=16). (L) Reduced number of Pvalb labeled interneurons in aCC 
of Brd1
+/-
 mice. Representative images of Pvalb expressing neurons in aCC (coronal sections) of 
WT and Brd1
+/-
 mice (top row). Stereological estimation shows an approximate 28% reduction in 
the number of Pvalb-labeled interneurons in aCC of Brd1
+/-
 mice (bottom row) (t test, p<0.05). cc; 
corpus callosum, L1; Cortical layer 1. *p<0.05, ***p<0.001 and ncells=number of neurons tested. 
Data shown are mean and SEM for each group unless specifically stated otherwise. 
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Figure 5 
Molecular changes converge in Dopamine-DARPP32-CREB signaling in Brd1
+/-
 mice.  
(A) Western blotting analysis of protein extracts derived from pulverized whole brains from WT 
(n=4) and Brd1
+/-
 mice (n=5). Membrane was incubated with anti-CREB and anti-c-FOS antibodies, 
stripped and subsequently incubated with anti-phospho-CREB (Ser133) (pCREB) and tubulin 
antibodies. Densitometric analysis of relative pCreb/Creb protein amounts showed an approximate 
40% increase in phosphorylated Creb protein in Brd1
+/-
 mice compared to WT mice and c-
Fos/Tubulin revealed an approximate 30% upregulation of c-Fos in Brd1
+/-
 mice. Data shown are 
mean + SEM for each group. *p<0.05. (B) DEGs, DEG enriched canonical pathways, and IPA 
predicted upstream regulators identified in the striatum of Brd1
+/-
 mice converge in G-protein 
coupled receptors (GPCR)/cAMP/PKA/DARPP-32/CREB signaling in GABAergic medium-sized 
spiny neurons (MSNs), the predominant cell type of the striatum. In short: The DARPP-32 
signaling pathway integrates information from a variety of neurotransmitters but mainly DA. In 
striatum, extracellular DA level is determined by a combination of mesolimbic DA activity and 
release probability at the synapse. Acetylcholine regulates the release probability through activation 
of nicotinic receptor heteromers containing α6 or α4 subunits and muscarinic receptor M2 and M4 
(61). Through GPCRs, DA regulate the activity of adenylyl cyclase (AC) and thereby cAMP 
production. cAMP activates PKA which can activate DARPP-32 (71) or directly activate AMPA 
receptors and thereby control corticostriatal neurotransmission (72). Glutamate induces calcium 
influx through activation of AMPA and NMDA receptors which indirectly de-activates DARPP-32. 
Dependent on phosphorylation status, DARPP-32 may then, through indirect mechanisms, facilitate 
activation of CREB and thus transcriptional regulation of immediate early genes (IEG), glutamate 
receptors, and numerous downstream physiological effectors ultimately affecting synaptic 
plasticity. Red asterisks mark DEGs, components of DEG enriched canonical pathways, and IPA 
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predicted upstream regulators identified in striatum of Brd1
+/-
 mice. For detailed description see 
Figure S12. Illustration adapted from Greengard et al. 1999 (73) and Berke et al. 2000 (74). 
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Table 1 | Summary of behavioral analysis in  Brd1
+/-
 mice 
 
Test 
Parameter measured 
Response
1
 
Specific implication to 
schizophrenia
2
 
Symptom domain 
Social interaction 
Passive interaction 
Latency to first interaction 
 
Decreased* 
Increased** 
Asociality/social 
withdrawal 
Negative Three chamber sociability test 
Sociability 
Social recognition 
Remote social memory 
 
Decreased*** 
NC 
Decreased* 
Asociality/social 
withdrawal 
Social cognition 
Spontaneous alternation 
-Basal 
-PCP 
 
NC 
Decreased* 
Working memory 
Cognitive 
Continuous alternation 
-Basal 
-PCP 
 
NC 
Decreased** 
Working memory 
Fear conditioning 
Conditioned learning 
Contextual memory 
-day 3 
-day 4 
 
Decreased** 
 
Decreased** 
Decreased*** 
Associative learning / 
memory 
(long term memory) 
ASR 
-Basal 
-PCP 
-Amphetamine 
 
Increased* 
NC 
NC 
Sensorimotor 
processing 
Cognitive/positive 
PPI 
-Basal 
-PCP 
-Amphetamine 
 
NC 
Decreased* 
NC 
Sensorimotor gating / 
Pre-attentive processing 
Spontaneous- and drug-
induced activity 
-Basal 
-PCP 
-Cocaine 
-Amphetamine 
 
 
NC 
Increased** 
Increased* 
NC 
Psychomotor agitation / 
Drug sensitivity 
Positive 
1) Brd1
+/-
 mice compared to WT littermates,
 
2) Possible relevance to the three symptom classes of 
schizophrenia (negative, cognitive, and positive). NC: No change. *p<0.05, **p<0.01, and 
***p<0.001 in statistical tests between genotypes. 
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